Therapeutic siRNA targeting PLIN2 ameliorates steatosis, inflammation, and fibrosis in steatotic liver disease models

• Published in: Journal of lipid research Vol. 65; no. 10; p. 100635
• Main Authors: Wang, Yao, Zhou, Jiaxin, Yang, Qi, Li, Xinmeng, Qiu, Yifu, Zhang, Yansong, Liu, Min, Zhu, Alan Jian
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.10.2024; American Society for Biochemistry and Molecular Biology; Elsevier
• Subjects: Animals; Disease Models, Animal; Fatty Liver - genetics; Fatty Liver - metabolism; Fatty Liver - pathology; fibrosis; GalNAc-siRNA; hepatic steatosis; Humans; inflammation; Inflammation - genetics; Inflammation - metabolism; Liver - metabolism; Liver - pathology; Liver Cirrhosis - genetics; Liver Cirrhosis - metabolism; Liver Cirrhosis - pathology; Male; MASLD; Mice; Mice, Inbred C57BL; Perilipin-2 - genetics; Perilipin-2 - metabolism; PLIN2; RNA, Small Interfering - metabolism; FDA; GTT; GalNAc-siRNA; HFD; ITT; ALT; MASH; PFA; gRNA; hepatic steatosis; inflammation; RT-qPCR; HYP; KI; AST; MASLD; GalNAc; TC; TG; BAT; HFr; PEI; sgRNA; AAV; PBST; LD; fibrosis; PLIN2

Metabolic dysfunction–associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide. If left untreated, MASLD can progress from simple hepatic steatosis to metabolic dysfunction–associated steatohepatitis, which is characterized by inflammation and fibrosis. Curren...